VYNE Therapeutics Inc.VYNEEarnings & Financial Report
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for dermatological conditions. Its product pipeline targets both common and underserved skin disorders, with primary operations and market reach across the United States, partnering with healthcare providers and specialty pharmacy networks to serve patients.
VYNE Q2 FY2025 Key Financial Metrics
Revenue
$69.0K
Gross Profit
N/A
Operating Profit
$-7.5M
Net Profit
$-5.8M
Gross Margin
N/A
Operating Margin
-10930.4%
Net Margin
-8340.6%
YoY Growth
-65.2%
EPS
$-0.13
VYNE Therapeutics Inc. Q2 FY2025 Financial Summary
VYNE Therapeutics Inc. reported revenue of $69.0K (down 65.2% YoY) for Q2 FY2025, with a net profit of $-5.8M (up 38.8% YoY) (-8340.6% margin).
Key Financial Metrics
| Total Revenue | $69.0K |
|---|---|
| Net Profit | $-5.8M |
| Gross Margin | N/A |
| Operating Margin | -10930.4% |
| Report Period | Q2 FY2025 |
VYNE Therapeutics Inc. Annual Revenue by Year
VYNE Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $501.0K).
VYNE Therapeutics Inc. Quarterly Revenue & Net Profit History
VYNE Therapeutics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $69.0K | -65.2% | $-5.8M | -8340.6% |
| Q1 FY2025 | $202.0K | +106.1% | $-8.6M | -4262.9% |
| Q4 FY2024 | $84.0K | +10.5% | $-12.0M | -14311.9% |
| Q3 FY2024 | $121.0K | +6.1% | $-12.2M | -10047.1% |
| Q2 FY2024 | $198.0K | +46.7% | $-9.4M | -4750.5% |
| Q1 FY2024 | $98.0K | -1.0% | $-6.2M | -6376.5% |
| Q4 FY2023 | $76.0K | +1166.7% | $-6.2M | -8142.1% |
| Q3 FY2023 | $114.0K | -31.7% | $-6.6M | -5775.4% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114000 | $76000 | $98000 | $198000 | $121000 | $84000 | $202000 | $69000 |
| YoY Growth | -31.7% | 1166.7% | -1.0% | 46.7% | 6.1% | 10.5% | 106.1% | -65.2% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $19.3M | $97.7M | $91.7M | $86.6M | $76.2M | $66.9M | $56.4M | $44.7M |
| Liabilities | $7.8M | $8.9M | $8.3M | $11.8M | $12.7M | $14.8M | $12.3M | $5.8M |
| Equity | $11.5M | $88.7M | $83.4M | $74.9M | $63.5M | $52.1M | $44.1M | $38.9M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.2M | $-5.1M | $-8.0M | $-8.5M | $-8.5M | $-9.0M | $-11.5M | $-10.8M |